A proteomic approach to identifying new drug targets (potentiating topoisomerase II poisons)

British Journal of Radiology

Volumn 81, Issue SPECIAL ISSUE, 2008, Pages

  Jenkins, John Roland ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE INHIBITOR; ETOPOSIDE; GELDANAMYCIN; HEAT SHOCK PROTEIN; HEAT SHOCK PROTEIN 90; PROTEIN P53; TANESPIMYCIN;

AMINO ACID SEQUENCE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER RESISTANCE; CANCER RISK; CHROMATIN ASSEMBLY AND DISASSEMBLY; CHROMOSOME ABERRATION; CHROMOSOME CONDENSATION; CHROMOSOME SEGREGATION; CLINICAL EFFECTIVENESS; CLINICAL PRACTICE; COLON CARCINOMA; CONFERENCE PAPER; DRUG POTENTIATION; DRUG TARGETING; ENZYME PHOSPHORYLATION; GENE EXPRESSION; GENETIC ASSOCIATION; GENETIC RECOMBINATION; GENETIC RISK; GENETIC TRANSCRIPTION; HEMATOLOGIC MALIGNANCY; HUMAN; LEUKEMIA; NONHUMAN; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; PROTEOMICS; SISTER CHROMATID EXCHANGE; SOLID TUMOR; TUMOR XENOGRAFT;

ANTINEOPLASTIC AGENTS; CHROMOSOMES, HUMAN; DNA TOPOISOMERASES, TYPE II; DRUG THERAPY, COMBINATION; ENZYME INHIBITORS; HEAT-SHOCK PROTEINS; HSP90 HEAT-SHOCK PROTEINS; HUMANS; NEOPLASMS; PEPTIDE FRAGMENTS; PHOSPHORYLATION; PROTEINS; PROTEOMICS; TRANSCRIPTION, GENETIC; TUMOR SUPPRESSOR PROTEIN P53;

EID: 55449131305     PISSN: 00071285     EISSN: None     Source Type: Journal    
DOI: 10.1259/bjr/76952340     Document Type: Conference Paper

References (55)

1. Tsai-Pflugfelder M, Liu LF, Liu AA, Tewey KM, Whang-Peng J, Knutsen T, et al. Cloning and sequencing of cDNA encoding human DNA topoisomerase II and localization of the gene to chromosome region 17q21-22. Proc Natl Acad Sci U S A 1988;85:7177-81.
2. Jenkins JR, Ayton P, Jones T, Davies SL, Simmons DL, Harris AL, et al. Isolation of cDNA clones encoding the beta isozyme of human DNA topoisomerase II and localization of the gene to chromosome 3p24. Nucleic Acids Res 1992;20:5587-92.
3. Austin CA, Sng JH, Patel S, Fisher LM. Novel HeLa topoisomerase II is the II beta isoform: complete coding sequence and homology with other type II topoisomerases. Biochim Biophys Acta 1993;1172:283-91.
4. Larsen AK, Escargueil AE, Skladanowski A. Catalytic topoisomerase II inhibitors in cancer therapy. Pharmacol Ther 2003;99:167-81.
5. Baldwin EL, Osheroff N. Etoposide, topoisomerase II and cancer. Curr Med Chem Anticancer Agents 2005;5:363-72.
6. Hammonds TR, Maxwell A, Jenkins JR. Use of a rapid throughput in vivo screen to investigate inhibitors of eukaryotic topoisomerase II enzymes. Antimicrob Agents Chemother 1998;42:889-94.
7. Li TK, Liu LF. Tumor cell death induced by topoisomerase-targeting drugs. Annu Rev Pharmacol Toxicol 2001;41:53-77.
8. Barker CR, Hamlett J, Pennington SR, Burrows F, Lundgren K, Lough R, et al. The topoisomerase II-Hsp90 complex: a new chemotherapeutic target? Int J Cancer 2006;118:2685-93.
9. Ackerman P, Glover CV, Osheroff N. Phosphorylation of DNA topoisomerase II by casein kinase II: modulation of eukaryotic topoisomerase II activity in vitro. Proc Natl Acad Sci U S A 1985;82:3164-8.
10. Bojanowski K, Filhol O, Cochet C, Chambaz EM, Larsen AK. DNA topoisomerase II and casein kinase II associate in a molecular complex that is catalytically active. J Biol Chem 1993;268:22920-6.
11. Park GH, Lee YT, Bae YS. Stimulation of human DNA topoisomerase II activity by its direct association with the beta subunit of protein kinase CKII. Mol Cells 2001;11:82-8.
12. Sahyoun N, Wolf M, Besterman J, Hsieh T, Sander M, LeVine H, 3rd, et al. Protein kinase C phosphorylates topoisomerase II: topoisomerase activation and its possible role in phorbol ester-induced differentiation of HL-60 cells. Proc Natl Acad Sci U S A 1986;83:1603-7.
13. DeVore RF, Corbett AH, Osheroff N. Phosphorylation of topoisomerase II by casein kinase II and protein kinase C: effects on enzyme-mediated DNA cleavage/religation and sensitivity to the antineoplastic drugs etoposide and 4′-(9-acridinylamino)methane-sulfon-m-anisidide. Cancer Res 1992;52:2156-61.
14. Reis C, Giocanti N, Hennequin C, Megnin-Chanet F, Fernet M, Filomenko R, et al. A role for PKCzeta in potentiation of the topoisomerase II activity and etoposide cytotoxicity by wortmannin. Mol Cancer Ther 2005;4:1457-64.
15. Mondal N, Zhang Y, Jonsson Z, Dhar SK, Kannapiran M, Parvin JD. Elongation by RNA polymerase II on chromatin templates requires topoisomerase activity. Nucleic Acids Res 2003;31:5016-24.
16. Kroll DJ, Sullivan DM, Gutierrez-Hartmann A, Hoeffler JP. Modification of DNA topoisomerase II activity via direct interactions with the cyclic adenosine-3′,5′-monophosphate response element-binding protein and related transcription factors. Mol Endocrinol 1993;7:305-18.
17. Zhou K, Choe KT, Zaidi Z, Wang Q, Mathews MB, Lee CG. RNA helicase A interacts with dsDNA and topoisomerase IIalpha. Nucleic Acids Res 2003;31:2253-60.
18. Zhang S, Grosse F. Nuclear DNA helicase II unwinds both DNA and RNA. Biochemistry 1994;33:3906-12.
19. Pirrotta V. Polycombing the genome: PcG, trxG, and chromatin silencing. Cell 1998;93:333-6.
20. Tong JK, Hassig CA, Schnitzler GR, Kingston RE, Schreiber SL. Chromatin deacetylation by an ATP-dependent nucleosome remodelling complex. Nature 1998;395:917-21.
21. Zhang Y, LeRoy G, Seelig HP, Lane WS, Reinberg D. The dermatomyositis-specific autoantigen Mi2 is a component of a complex containing histone deacetylase and nucleosome remodeling activities. Cell 1998;95:279-89.
22. Tsai SC, Valkov N, Yang WM, Gump J, Sullivan D, Seto E. Histone deacetylase interacts directly with DNA topoisomerase II. Nat Genet 2000;26:349-53.
23. Johnson CA, Padget K, Austin CA, Turner BM. Deacetylase activity associates with topoisomerase II and is necessary for etoposide-induced apoptosis. J Biol Chem 2001;276:4539-42.
24. Escargueil AE, Plisov SY, Skladanowski A, Borgne A, Meijer L, Gorbsky GJ, et al. Recruitment of cdc2 kinase by DNA topoisomerase II is coupled to chromatin remodeling. Faseb J 2001;15:2288-90.
25. Durrieu F, Samejima K, Fortune JM, Kandels-Lewis S, Osheroff N, Earnshaw WC. DNA topoisomerase IIalpha interacts with CAD nuclease and is involved in chromatin condensation during apoptotic execution. Curr Biol 2000;10:923-6.
26. Lin S, Hickey RJ, Malkas LH. The isolation of a DNA synthesome from human leukemia cells. Leuk Res 1997;21:501-12.
27. Hickey RJ, Malkas LH. Mammalian cell DNA replication. Crit Rev Eukaryot Gene Expr 1997;7:125-57.
28. Matheos D, Ruiz MT, Price GB, Zannis-Hadjopoulos M. Ku antigen, an origin-specific binding protein that associates with replication proteins, is required for mammalian DNA replication. Biochim Biophys Acta 2002;1578:59-72.
29. Bhat MA, Philp AV, Glover DM, Bellen HJ. Chromatid segregation at anaphase requires the barren product, a novel chromosome-associated protein that interacts with Topoisomerase II. Cell 1996;87:1103-14.
30. Wang X, Watt PM, Louis EJ, Borts RH, Hickson ID. Pat1: a topoisomerase II-associated protein required for faithful chromosome transmission in Saccharomyces cerevisiae. Nucleic Acids Res 1996;24:4791-7.
31. Watt PM, Louis EJ, Borts RH, Hickson ID. Sgs1: a eukaryotic homolog of E. coli RecQ that interacts with topoisomerase II in vivo and is required for faithful chromosome segregation. Cell 1995;81:253-60.
32. Morrison C, Henzing AJ, Jensen ON, Osheroff N, Dodson H, Kandels-Lewis SE, et al. Proteomic analysis of human metaphase chromosomes reveals topoisomerase II alpha as an Aurora B substrate. Nucleic Acids Res 2002;30:5318-27.
33. Adams RR, Carmena M, Earnshaw WC. Chromosomal passengers and the (aurora) ABCs of mitosis. Trends Cell Biol 2001;11:49-54.
34. Valkov NI, Sullivan DM. Tumor p53 status and response to topoisomerase II inhibitors. Drug Resist Updat 2003;6:27-39.
35. Levesque AA, Eastman A. p53-based cancer therapies: Is defective p53 the Achilles heel of the tumor? Carcinogenesis 2007;28:13-20.
36. Kwon Y, Shin BS, Chung IK. The p53 tumor suppressor stimulates the catalytic activity of human topoisomerase IIalpha by enhancing the rate of ATP hydrolysis. J Biol Chem 2000;275:18503-10.
37. Karpinich NO, Tafani M, Rothman RJ, Russo MA, Farber JL. The course of etoposide-induced apoptosis from damage to DNA and p53 activation to mitochondrial release of cytochrome c. J Biol Chem 2002;277:16547-52.
38. Sandri MI, Isaacs RJ, Ongkeko WM, Harris AL, Hickson ID, Broggini M, et al. p53 regulates the minimal promoter of the human topoisomerase IIalpha gene. Nucleic Acids Res 1996;24:4464-70.
39. Wang Q, Zambetti GP, Suttle DP. Inhibition of DNA topoisomerase II alpha gene expression by the p53 tumor suppressor. Mol Cell Biol 1997;17:389-97.
40. Kim HD, Tomida A, Ogiso Y, Tsuruo T. Glucose-regulated stresses cause degradation of DNA topoisomerase IIalpha by inducing nuclear proteasome during G1 cell cycle arrest in cancer cells. J Cell Physiol 1999;180:97-104.
41. Ogiso Y, Tomida A, Lei S, Omura S, Tsuruo T. Proteasome inhibition circumvents solid tumor resistance to topoisomerase II-directed drugs. Cancer Res 2000;60:2429-34.
42. Isaacs RJ, Davies SL, Sandri MI, Redwood C, Wells NJ, Hickson ID. Physiological regulation of eukaryotic topoisomerase II. Biochim Biophys Acta 1998;1400:121-37.
43. Gerke V, Moss SE. Annexins: from structure to function. Physiol Rev 2002;82:331-71.
44. Cole SP, Pinkoski MJ, Bhardwaj G, Deeley RG. Elevated expression of annexin II (lipocortin II, p36) in a multidrug resistant small cell lung cancer cell line. Br J Cancer 1992;65:498-502.
45. Zhang P, Liu B, Kang SW, Seo MS, Rhee SG, Obeid LM. Thioredoxin peroxidase is a novel inhibitor of apoptosis with a mechanism distinct from that of Bcl-2. J Biol Chem 1997;272:30615-8.
46. Kaufman RJ. Molecular chaperones and the heat shock response. Biochim Biophys Acta 1999;1423:R13-27.
47. Concannon CG, Gorman AM, Samali A. On the role of Hsp27 in regulating apoptosis. Apoptosis 2003;8:61-70.
48. Dastoor Z, Dreyer J. Nuclear translocation and aggregate formation of heat shock cognate protein 70 (Hsc70) in oxidative stress and apoptosis. J Cell Sci 2000;113:2845-54.
49. Johnson BD, Schumacher RJ, Ross ED, Toft DO. Hop modulates Hsp70/Hsp90 interactions in protein folding. J Biol Chem 1998;273:3679-86.
50. Mouchel NA, Jenkins JR. The identification of a functional interaction between PKC and topoisomerase II. FEBS Lett 2006;580:51-7.
51. Barker CR, Mouchel NA, Jenkins JR. The identification and characterization of a functional interaction between arginyl-tRNA-protein transferase and topoisomerase II. Biochem Biophys Res Commun 2006;342:596-604.
52. Barker CR, McNamara AV, Rackstraw SA, Nelson DE, White MR, Watson AJ, et al. Inhibition of Hsp90 acts synergistically with topoisomerase II poisons to increase the apoptotic killing of cells due to an increase in topoisomerase II mediated DNA damage. Nucleic Acids, Res 2006;34:1148-57.
53. Blagosklonny MV, Fojo T, Bhalla KN, Kim JS, Trepel JB, Figg WD, et al. The Hsp90 inhibitor geldanamycin selectively sensitizes Bcr-Abl-expressing leukemia cells to cytotoxic chemotherapy. Leukemia 2001;15:1537-43.
54. Arlander SJ, Eapen AK, Vroman BT, McDonald RJ, Toft DO, Karnitz LM. Hsp90 inhibition depletes Chk1 and sensitizes tumor cells to replication stress. J Biol Chem 2003;278:52572-7.
55. Wyles JP, Wu Z, Mirski SE, Cole SP. Nuclear interactions of topoisomerase II alpha and beta with phospholipid scramblase 1. Nucleic Acids Res 2007;35:4076-85.